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Abstract
Risks for disease in some population groups relative to others (relative risks) are usually 
considered to be consistent over time, though they are often modified by other, non-temporal 
factors. For infectious diseases, in which overall incidence often varies substantially over time, the 
patterns of temporal changes in relative risks can inform our understanding of basic epidemiologic 
questions. For example, recent work suggests that temporal changes in relative risks of infection 
over the course of an epidemic cycle can both be used to identify population groups that drive 
infectious disease outbreaks, and help elucidate differences in the effect of vaccination against 
infection (that is relevant to transmission control) compared with its effect against disease episodes 
(that reflects individual protection). Patterns of change in the in age groups affected over the 
course of seasonal outbreaks can provide clues to the types of pathogens that could be responsible 
for diseases for which an infectious cause is suspected. Changing apparent efficacy of vaccines 
during trials may provide clues to the vaccine's mode of action and/or indicate risk heterogeneity 
in the trial population. Declining importance of unusual behavioral risk factors may be a signal of 
increased local transmission of an infection. We review these developments and the related public 
health implications.
Introduction
Many infections, particularly those of childhood, give rise to recurrent epidemics with a 
period of one or several years. This pattern is produced by the rapid spread of infection 
through a population with many susceptible persons, followed by a peak and decline in 
incidence as susceptible hosts become immune following infection, depriving the epidemic 
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of “fuel” to continue spreading. New births, immigration, waning immunity of those who 
were previously infected, or evolution of the pathogen to escape existing immunity may 
replenish the pool of susceptible hosts, setting up conditions for another epidemic. Sustained 
occurrence of repeated, periodic epidemics [1] is also driven by seasonal variation in 
transmission opportunities that are affected by seasonal aggregation of children in schools 
[2,3], seasonal variation in pathogen survival [4] and/or host susceptibility [5,6], 
coinfections [7,8], vector abundance [9], or other factors.
While these classic drivers of infectious disease epidemics have been studied extensively, 
there has thus far been relatively limited study of how the association between specific 
characteristics of hosts (e.g. age, risk behavior, travel history, treatment history, etc.) and the 
risk of disease changes with time. A closer examination of such change can be greatly 
informative about the underlying disease processes and also may suggest opportunities for 
targeted control strategies. Improving collaboration between those who study risk factors for 
infectious diseases and those who study their transmission dynamics could help reduce this 
historical disconnect [10,11].
Characterizing the temporal variation in the risk of infectious diseases among certain 
population groups relative to other groups not only facilitates up-to-date evaluation of who is 
likely to contract a disease, but also has surprising value in answering a number of basic 
epidemiologic questions. These include: identifying the population subgroups most 
important for transmission of an infection, estimating components of vaccine effectiveness, 
and addressing biases in studies of the effectiveness of interventions (e.g. vaccines) or risk 
factors for infection. Here, we review work on a variety of infectious diseases, surveying a 
range of epidemiologic inferences that can be drawn from temporal changes in relative risks 
of infection between different population groups. In each section, we highlight the key 
insight that drives the inferences from changes in relative risks, spelling out the necessary 
assumptions, then give several examples of the inferences that can be drawn.
Trends relative to the stage of the epidemic curve
Key insight
Final attack rates across different population groups (e.g. age categories) are commonly 
reported for outbreaks, but the relative incidence in different population groups can vary in 
meaningful ways over the course of an outbreak. This happens because certain population 
groups have above-average risks of infection (e.g. due to differences in exposure to infection 
and/or pre-existing immunity). Such high-risk groups are overrepresented among incident 
cases during the outbreak's early stages; hence the proportion of susceptible individuals in 
these groups is depleted more rapidly compared to other population groups. As a result, 
there are fewer individuals among the high-risk groups who remain susceptible to infection 
during the later stages of an epidemic compared to the general population. Correspondingly, 
the proportion of individuals belonging to the high-risk group(s) among all incident cases 
decreases over time. This phenomenon can be demonstrated in a transmission modeling 
framework, such as in Koopman et al. [12].
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Application: Identification of driver groups in infectious disease outbreaks
Our understanding of the role of different population groups in the dynamics of most 
infectious disease outbreaks remains limited because the transmission process is largely 
unobserved. Transmission modeling has provided numerous insights into the underlying 
processes; however, it is difficult to calibrate transmission models and ascertain their 
reliability for several reasons. These include: uncertainty about the key variables (age, 
household structure, contact rates) essential to characterize transmission of each infection 
[13,14]; data limitations including variation in reporting rates of infection as a function of 
age and other variables [15,16], and the need for possibly unrealistic simplifying 
assumptions in order to make transmission rate parameters identifiable from available data 
[13]. Therefore, it is desirable to have statistical tools that make use of limited data, usually 
obtained from detected cases during infectious disease outbreaks, to make conclusions about 
the role of different population groups in propagating the spread of infection, the impact of 
vaccination, and other phenomena. Examples of such summary statistics that characterize 
temporal changes in the distribution of cases during epidemics were described by Worby et 
al. [17,18]. We describe those methods below in the context of influenza and pertussis 
epidemics.
Driver groups during influenza outbreaks
While major influenza epidemics take place in the US almost every season with a substantial 
burden of morbidity and mortality, the relative importance of different age groups in driving 
influenza epidemics is not fully understood. School-aged children (aged 5-17) were found to 
have experienced the highest influenza attack rate during the 2009 A/H1N1 pandemic [19]. 
For the pre-pandemic period, a series of studies using consistent methodology found that 
during certain influenza seasons, attack rates for influenza A infections were highest for 
school-age children [20], while for other seasons, attack rates were relatively similar across 
the different age groups [21]. In the post-pandemic period, the relative roles of age groups 
other than school-age children during influenza A/H1N1 epidemics have apparently 
increased, both in the US and abroad [17,22]. Additionally, a good deal of uncertainty exists 
as to the drivers of influenza B outbreaks. Studies based on transmission modeling have 
suggested the key role of school-age children in propagating influenza epidemics [23,24]. 
However, these conclusions hinge on certain assumptions related to mixing between the 
different age groups, distribution of susceptibility to infection within each age group, etc., 
whose reliability is difficult to ascertain. Moreover, those models are rarely calibrated 
against data from specific influenza seasons, particularly outside the pandemic context.
One approach to identifying driver groups in infectious disease outbreaks is to look for 
groups that are disproportionately represented among incident cases during the ascent of the 
outbreak due to either increased contact rates (raising the risk of exposure) or increased 
susceptibility (raising the risk of infection upon exposure) [17]. Such groups experience a 
disproportionate depletion of susceptible members during the outbreak's early stages and 
represent a relatively smaller proportion of all cases of infection in the population during the 
outbreak's later stages. Figure 1 exhibits this phenomenon for children aged 10-14 during the 
2010 pertussis epidemic in California (see also Figure 1 in [18] for the 2012 pertussis 
epidemic in Minnesota). Change in the relative risk of disease among different groups can be 
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captured by the summary statistic RR (age-specific risk ratio) defined as the ratio of the 
proportion of a given age group g among all detected cases before the epidemic peak (Bp(g)) 
and the corresponding proportion after the epidemic peak (Ap(g)):
(1)
Figure 2 illustrates the RR concept for a simulated epidemic in an age-stratified population. 
Note that “detected” cases are used in the above definition because the incidence of 
influenza infections in different age groups is notoriously difficult to measure accurately. 
However, the definition of RR will work even with a proxy for incidence (detected cases) 
provided that this proxy is proportional to incidence within each population group. For 
example, the proxy used by Worby et al. [17] was weekly counts of hospitalizations with 
laboratory-confirmed influenza infection. Importantly, while case detection (in this instance, 
hospitalization) rates may be highly age specific, they are not expected to vary over time 
within a particular age group. As a consequence, the ratio of the summary statistics RR for 
any pair of age groups g1 and g2 (OR(g1,g2)=RR(g1)/RR(g2)) is independent of the age-
specific case detection rates [18], as long as these rates in each age group remain unchanged 
over the course of the epidemic, or all change by the same factor. This ratio can be used to 
statistically differentiate the relative prominence of different age groups during the 
outbreak's ascent (see e.g. Table 2 in [18]).
Application of the summary statistic RR permitted inferences about several issues that were 
unsettled using other methods: the prominence of school-age children and the minor role of 
older adults in propagating major influenza A epidemics; differences in the driver groups for 
influenza A and B; and the lesser role of children 5-17 for influenza A/H1N1 epidemics 
compared to A/H3N2 epidemics since the 2009 pandemic [17].
A key question is whether such a simple RR statistic can reliably identify population groups 
that “drive” epidemics. While “driver group” is a somewhat vague concept, its meaning can 
be addressed by considering the potential impact of targeting vaccination to different 
population groups. Simulations in a transmission modeling framework based on a variety of 
scenarios suggested that the summary statistic RR is closely related to vaccine prioritization; 
namely, for larger outbreaks, the age group with the highest value of RR is also the group for 
which allocation of a fixed quantity of a vaccine early in the epidemic would yield the 
largest reduction in the epidemic's initial effective reproductive number [17]. Moreover, 
results in Worby et al. [17] suggest that for the larger influenza A epidemics, this group is 
consistently represented by children aged 5-17, with that conclusion likely being 
generalizable to major future influenza A outbreaks.
An earlier method for assessing driver groups in infectious disease outbreaks was presented 
by Wallinga et al. [25]. This method is based on the same idea but requires more precise 
data, namely estimates of actual incidence (rather than incidence proxies) in different 
population groups. Such estimates generally require serological data [25], as symptomatic or 
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reported infection typically represents an unknown and age-specific proportion of 
serologically evident infections.
Driver groups during pertussis outbreaks
Pertussis is the most common reportable and vaccine-preventable disease in the US, and in 
recent years, large outbreaks have occurred in several US states despite high vaccination 
coverage [26]. The continuing upward shift in the age distribution of pertussis cases, often 
attributed to the switch to the acellular pertussis vaccine series that took place around 1998, 
is expected to result in even larger outbreaks in the future (as exemplified by the 2014 vs. the 
2010 epidemics in California).
As with seasonal influenza, the transmission dynamics of pertussis and the relative roles 
played by the different age groups are still imperfectly understood [27]. Disease is typically 
most severe for young children. It is thought that grade school students, adolescents, and 
teenagers all play a major role in pertussis transmission [28,29], though limited information 
exists to quantify those relative roles and the changes in those roles in recent years.
To examine the impact of the different age groups during the 2012 pertussis outbreak in 
Minnesota, an inference framework similar to that used for influenza [17] was employed by 
Worby et al. [18]. The results highlight the important role played by children aged 8–14, 
particularly 11-12 year olds, in driving the 2012 outbreak in Minnesota. These results, if 
found to be consistent across different recent outbreaks, combined with simulations in a 
transmission modeling framework [18], suggest that providing additional protection against 
pertussis infection for those groups should reduce the risk of large outbreaks, thereby 
protecting vulnerable sub-populations, particularly infants.
Driver groups for other infectious diseases
Another way to summarize the changing age-profile of infection during the course of an 
epidemic is by the correlation between mean age in a given week and incidence in that 
week, which we refer to as the age-incidence pattern [30]. By examining the correlation 
coefficient between the weekly incidence of observed cases and the average age of such 
cases at different lags, it was shown that determining whether this correlation is highest at 
negative versus positive lags (i.e. whether the average age is greatest before or after the 
epidemic peak) helps to identify which age groups are more likely to be infected early on in 
the epidemic [30].
Such an analysis revealed that data on pre-vaccination rotavirus hospitalizations in the 
United States and measles notifications in Denmark exhibited opposite patterns: for 
rotavirus, the peak correlation occurred at a positive lag, meaning the average age of cases 
was greatest after the peak of the epidemic, while for measles, the peak correlation occurred 
at a negative lag, meaning the average age of cases was greatest before the epidemic peak. 
These observations are consistent with infants (who are younger than the mean age of 
rotavirus cases) being the primary drivers of rotavirus transmission, and school-aged 
children (who are older than the mean age of measles cases) being the primary drivers of 
measles transmission in the respective settings. This analysis showed that transmission 
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models could reproduce these patterns only when they took into account the epidemiologic 
importance of these driver groups.
Effect of a vaccine against infection
Studies of vaccine efficacy for different pathogens often report efficacy against medically 
attended or symptomatic, laboratory-confirmed infection. For pathogens like pertussis and 
rotavirus, the ability of vaccines to prevent infection, as opposed to symptomatic or 
medically attended disease, remains unclear. Only a small fraction of infections with these 
pathogens, particularly in the non-infant age groups, result in detectable disease episodes 
[31,32], yet one important goal of vaccination is to prevent infection in older children in 
order to create herd immunity to protect the most vulnerable populations. For pertussis, 
different vaccine formulations may have different effects on the risk of infection. In the US, 
children receive five diphtheria, tetanus and acellular pertussis (DTaP) vaccines before the 
age of 7 years. In 2005, a booster vaccine (tetanus, reduced diphtheria, and reduced acellular 
pertussis (Tdap)) was introduced and recommended at age 11–12 years in response to an 
increasing number of reported cases in adolescents.
Both DTaP and Tdap have good efficacy against detectable pertussis disease, though this 
protection wanes over time [33-37]. However, effectiveness of pertussis vaccines against 
infection and transmission in the community is much less certain. While there is some 
epidemiologic evidence for herd immunity induced by DTaP campaigns in younger children 
[38], no analogous results for Tdap are known. In fact, a recent study has found that infant 
baboons vaccinated with an acellular pertussis vaccine can be asymptomatically infected and 
transmit onward [39].
Pertussis vaccine effectiveness against infection for both DTaP and Tdap was assessed by 
examining the temporal variation in the relative risk for infection for vaccinated vs. 
unvaccinated children [18]. This analysis was based on the odds ratio (OR) within an age 
group g for being unvaccinated vs. vaccinated for the epidemic's descent vs. ascent periods. 
This OR statistic is closely related to the RR statistic given by eq. 1, namely
(2)
For DTaP, this analysis found that unvaccinated individuals were overrepresented during the 
epidemic's ascent (OR>1) compared to vaccinated individuals, suggesting faster depletion of 
the unvaccinated than the vaccinated population during the epidemic wave. This implies that 
DTaP vaccination protects against infection, a finding that is consistent with earlier studies 
[38]. In contrast, there was no evidence of differences in the Tdap vaccination status of cases 
aged 11–14 years between the ascent and descent of the outbreak (95% confidence intervals 
for this OR included 1), suggesting no evidence for protection of Tdap against pertussis 
infection during an outbreak. This finding is consistent with the baboon observations 
reported in Warfel et al. [39]. This lack of evidence for Tdap's effect, however, may be a 
result of an underpowered study, and further work is needed to determine the role of Tdap in 
protection against pertussis infection.
Goldstein et al. Page 6
Epidemiology. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Identifying the etiology of diseases of unknown cause
Examining changes in the age distribution of cases over the course of recurrent epidemics 
can also help to identify features of the possible pathogens causing diseases of unknown 
etiology. One such disease for which an infectious cause is suspected, but the etiologic agent 
has proven elusive, is Kawasaki disease. Kawasaki disease is an acute systemic vasculitis 
characterized by prolonged fever along with a constellation of clinical signs, including rash, 
changes to the mucous membranes, lymphadenopathy, and non-purulent conjunctivitis [40]. 
It is the leading cause of acquired heart disease in children from high-income countries, and 
there is genetic variation in susceptibility [41]. A model was constructed to examine how the 
age-incidence pattern for Kawasaki disease hospitalizations in the United States would vary 
depending on assumptions about characteristics of the pathogen(s) involved, such as the 
duration of infection and the presence or absence of lifelong immunity to reinfection [30].
The results suggested that the age-incidence pattern of Kawasaki disease, in which the 
average age of cases tended to greatest near the trough of seasonal epidemics, is inconsistent 
with the pattern predicted for a single acute infection under most assumptions regarding 
immunity and population mixing. Instead, it was suggested that Kawasaki disease is more 
likely to be caused by a pathogen with a long duration of infection, such as a colonizing 
bacterium, or co-infection with an acute pathogen and one with a long duration of infection. 
Thus, examining age-incidence patterns can lend some insight into the search for the 
causative agent of Kawasaki disease by narrowing the field of potential candidates and 
supporting the hypothesis that it may involve co-infection with more than one pathogen.
Trends relative to time since the commencement of a vaccine trial
Key insight
In vaccine efficacy or effectiveness trials, initial rates of infection will be higher in the 
unvaccinated vs. the vaccinated arm of the study if the vaccine has some efficacy. The 
disproportionate initial depletion of susceptible individuals in the unvaccinated arm (Figure 
1 in [42]) can cause the rates of infection in each study arm to become more similar over 
time, potentially giving a false impression that the vaccine's effectiveness was decreasing 
even in the absence of waning immunity or behavior change [43-45]. Similar biases may 
also affect the results of observational (e.g. case–control) vaccine effectiveness studies, as 
well as studies of other interventions and investigations of risk factors.
Epidemiologic evidence and recipes for bias removal
In two recent HIV prevention studies, the RV144 vaccine and CAPRISA 004 microbicide 
trials [43], the relative risk of infection among individuals receiving the intervention 
increased towards the null value of one over time. Here, the relative risk for infection at time 
t since the beginning of the trial is measured as
(3)
Goldstein et al. Page 7
Epidemiology. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
where ARt is the attack rate (proportion of individuals who got infected) by time t. 
Correspondingly, vaccine (or intervention) effectiveness (VE) by time t is estimated as
(4)
Similar apparent decline in intervention effectiveness estimated by eq. 4 is observed in other 
studies, such as those conducted annually to produce early, mid-season, and end season 
estimates of influenza vaccine effectiveness in the US (e.g. [46] vs. [47] vs. [48]).
Various possible reasons for the observed declines in effectiveness, such as waning of 
vaccine-induced immunity or declining adherence to microbicide use, have been proposed 
by O'Hagan et al. [43]. A further explanation for why VE estimates can appear to decline 
with time was suggested by Smith et al. [42] and has to do with the vaccine's mode of action. 
Briefly, two simple modes of action are considered in Smith et al. [42]:
1. Leaky vaccine, reducing susceptibility to infection per contact by a 
fraction F in all individuals.
2. All-or-nothing vaccine, making a fraction F of individuals completely 
immune and having no effect on the rest.
Smith et al. [42] showed that, for a leaky vaccine, estimates of effectiveness given by eq. 4 
decrease with time, whereas estimates of effectiveness for an all-or-nothing vaccine are 
temporally invariant (and equal to F). While both these models of vaccine action are 
simplifications of reality, differences in the estimates of VE provided by those models 
highlight an important phenomenon. Specifically, in the leaky model, depletion of the pool 
of susceptible individuals occurs at a higher rate for the unvaccinated cohort compared to the 
vaccinated cohort because individuals in the former cohort are more susceptible to infection. 
As a result, the relative risk for infection in the vaccinated cohort compared to the 
unvaccinated one increases with time, and the estimate of VE decreases with time. Thus, 
estimates of VE based on comparing relative risks during the second year of a vaccine trial, 
for example, will be biased because the vaccinated and unvaccinated arms are no longer 
comparable in their infection history, even if randomization at baseline was successful.
Figure 3 illustrates those phenomena for a simulated influenza epidemic (see also Figure 2B 
in [49]). Note that the incidence curve in the vaccinated population is shifted to the right 
compared to the unvaccinated population, resulting in the temporal decline for the estimates 
of VE.
Actual vaccines are believed to be leaky to various degrees, although there is very limited 
direct evidence on this point [50]. Correspondingly, temporal decline in risk-based VE 
estimates in epidemiologic studies is expected to be a general phenomenon, and such 
declines due to differential depletion of hosts in the two arms over time cannot be easily 
separated from declines in VE due to possible waning immunity.
Various approaches exist for addressing potential sources of bias in estimating vaccine 
efficacy. Smith et al. [42] proposed that one should consider person–years at risk, defined as 
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time to either infection or to the end of the trial, to devise a rate-based estimate of vaccine 
efficacy. These ideas have been further developed in a series of papers by Halloran, Longini, 
Struchiner, and colleagues [44,51], where their limitations are also discussed. A scheme for 
statistical interpretation of vaccine efficacy trials in a Bayesian framework is presented by 
Gilbert et al. [52]. Auvert et al. [53] proposed that crossover-type study designs could be 
implemented for addressing temporal variability in infection rate ratios when reversible 
interventions are being studied (e.g. prophylaxis, where participants can be randomized first 
to the active treatment arm and later to placebo, and vice versa). This is an area in need of 
further methodological development, and in the meantime it will be valuable to consider 
competing hypotheses for temporal patterns observed when reporting and comparing 
vaccine effectiveness or efficacy for various time periods in a study.
If individuals are heterogeneous in terms of their risk of infection, that heterogeneity may 
further synergize with the effect of vaccination to contribute to the temporal decline in the 
estimates of VE. Briefly, this happens because individuals with the highest risk of infection 
experience the largest rates of depletion of susceptible individuals, contributing the most to 
the relative change in the pool of susceptible individuals in the unvaccinated vs. vaccinated 
arm. The potential impact of heterogeneity in infection risk (frailty) on trial results is 
explored in more detail by O'Hagan et al. [43].
Trends relative to prevalence and incidence: risks associated with atypical 
activities
Key insight
Coming into contact with another infectious individual in the community is generally 
necessary for becoming infected, though such contacts are typically not measured and are 
often unmeasurable. When the risk of becoming infected through one type of exposure is 
low, other risk factors will come to the forefront. Understanding how and why risk factors 
vary with prevalence can lend useful insights. The higher the prevalence of a particular 
infection or strain in a community, the less “unusual” will be the persons who get infected. 
Thus, risk factors indicating atypical activities that may be conducive to acquisition of 
infection can often weaken as prevalence increases, providing evidence for transmission 
among a broader segment of the population.
Example: HIV epidemic in Mexico
During the early stages of the HIV epidemic in Mexico (and other places), blood transfusion 
was an important source of infection, particularly in persons who did not have other high-
risk exposures. Under such circumstances, extra monitoring for recipients of blood 
transfusion may be warranted to mitigate further spread of infection in the community. 
When prevalence of infection in the community increases, one expects that the relative risk 
of infection by virtue of being a recipient of blood transfusion will decrease. This intuition 
was confirmed by Volkow et al. [54], where the proportion of women in Mexico with HIV 
infection who acquired it through blood transfusion decreased noticeably with time. We note 
that besides increases in HIV prevalence, another factor, namely improvements in the safety 
of blood transfusion through increased screening in Mexico, also contributed to the above 
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decline. The results of Volkow et al. [54] suggest the need for a separate study to disentangle 
the contributions of each factor.
Example: Antimicrobial resistant gonorrhea
Between 2001-2007, there was a sharp rise in the proportion of infections with Neisseria 
gonorrhoeae in the US that were resistant to ciprofloxacin, the primary antibiotic 
recommended for treatment of gonorrhea at the time. With a looming possibility of an 
epidemic of gonorrhea resistant to the injectable cephalosporins, currently the only class of 
antimicrobials recommended as primary agents for gonorrhea treatment (given in 
conjunction with a 1g azithromycin dose as part of dual therapy) in the US, an 
understanding of the risk factors for drug resistant gonorrhea is desirable for the purpose of 
administering extra screening and prevention efforts for certain categories of individuals.
Factors related to prevalence of ciprofloxacin resistance between 2001-2007 in the US were 
examined by Goldstein et al. [55]. During the early stages of emergence of antimicrobial 
resistance in N. gonorrhoeae, recent travel was a risk factor for resistance in gonorrhea cases 
[55]. During the later stages of that epidemic when resistance was established in the 
community, the proportion of cases with recent travel history among all resistant cases 
decreased, and the association with travel had disappeared, suggesting local spread of 
resistant infections, particularly of multi-drug resistant N. gonorrhoea strains among men 
who have sex with men [55].
Example: Antiviral treatment and resistance during influenza epidemics
In an emerging influenza pandemic, limited options exist for mitigating its impact in the 
community. One possible mitigation strategy is extensive usage of antiviral medications. 
However, studies suggest some strains of influenza may become resistant to oseltamivir 
(currently the primary antiviral agent used for treatment of influenza infections) while 
maintaining infectiousness [56,57]. Use of antiviral medications during epidemics may 
therefore give rise to de novo resistant cases (new cases of resistance resulting from antiviral 
treatment of sensitive influenza strains) and antiviral resistance may proliferate in the 
community. Using a transmission-dynamic model, it was shown by Lipsitch et al. [58] that 
treatment of a fixed proportion of influenza infections with antivirals can select for a 
resistant strain that outcompetes the sensitive strain (provided that its intrinsic fitness is not 
too low compared to the sensitive strain). Moreover, during the early stages of an epidemic, 
receiving antiviral treatment is an important risk factor for resistant infection. However, as 
the epidemic progresses, the relative prevalence of resistant strains among all infections 
increases. Correspondingly, among resistant cases of infection, the proportion of de novo 
cases decreases with time and antiviral treatment becomes less of a risk factor for carrying a 
resistant strain.
Discussion
It seems natural that infectious diseases, which vary greatly over time in incidence and 
prevalence, may also be dynamic in terms of the relative risk they present to different groups 
in the population. In this way, risk factor analysis for infectious disease epidemiology cannot 
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always be accommodated by the classical epidemiologic models (which are often motivated 
by questions in chronic disease epidemiology, where relative risks often change very slowly 
over time). For example, the commonly used Cox proportional hazards model assumes that 
the ratio of hazards for different types of individuals is temporally invariant, which is 
contrary to the situation for the hazards for getting infected during infectious disease 
outbreaks. At the same time, understanding the change over time in relative risks for 
infection can be informative about such diverse questions in the science of public health as 
disease etiology, vaccine effectiveness, and the role of particular age groups in propagating 
epidemics. These considerations suggest that new statistical techniques are needed to 
address temporal changes in relative risks for infection. This review describes some of the 
recently introduced relevant statistical methodology and presents a number of contexts in 
which such analyses can yield insight into public health-related questions.
There remain several examples of changing relative risks over time that are readily 
documented but difficult to explain mechanistically. One such change that has been observed 
and appropriately celebrated, but not explained, is the decline in the elevated relative risk of 
invasive pneumococcal disease for African Americans in the era of the pneumococcal 
conjugate vaccine [59]. Another, more complex example is the changing roles of hospital 
and community exposures in determining the risk of methicillin-resistant Staphylococcus 
aureus infection [60]. Additional work is required to understand these and similar 
phenomena.
One category of explanation for changing relative risks over time that we have not addressed 
directly is pathogen evolution. Different host populations and different modes of spread may 
impose different selection pressures on infectious agents, and the appearance (for example) 
of a new pathogen strain that is well-equipped for a particular environment or host 
population may be another cause for changes in who is at risk for infection. For example, 
changing profiles of the population at risk for particular bacterial infections have been linked 
to new pathogen strains carrying genes involved in adhesion to host tissues [61] or toxins 
[62]. A parallel literature in molecular epidemiology of pathogens (e.g. [63]) documents the 
rise and fall of particular pathogen lineages over time, with less attention to which kinds of 
hosts tend to get infected with which genetic variants. Combining epidemiologic analysis of 
host risk factors (and their change over time) with molecular analysis of pathogen 
characteristics (and their change over time) may be a fertile route to understanding the 
relationship between who gets infected and which pathogen or strain infects them.
More generally, the examples adduced in this review suggest that relative risks for infection 
may change for any number of reasons, and that it should be a routine part of data analysis 
in infectious disease epidemiology to visualize the changes over time in relative risks for 
infection, subject those changes to statistical analyses akin to the ones described in this 
review, and to consider potential explanations for these changes when they are observed. 
Such assessment may produce signals about the various relevant epidemiologic phenomena 
or, alternatively, indicate that a time-invariant mechanism is adequate to explain the data.
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Figure 1. 
Monthly incidence of detected pertussis cases, and proportions of children aged 0-4 and 
10-14 among those cases, California, 2010. Data from the US CDC.
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Figure 2. 
Total daily incidence of infection, incidence among children, proportions of children among 
incident cases before and after the epidemic peak, and the risk ratio RR for children (eq. 1) 
for a simulated epidemic in a stratified population.
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Figure 3. 
(A) Daily incidence of influenza infection (per 1,000) in the unvaccinated and vaccinated 
populations. (B) Vaccine effectiveness VE(t) by day t, estimated via eq. 4. Actual vaccine 
efficacy (leaky vaccine) is 60%.
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